title: Combination of intravenous immunoglobulins and lenalidomide in the treatment of scleromyxedema.
authors.forename: Florence
authors.initials: F
authors.lastname: Brunet-Possenti
authors.forename: Olivier
authors.initials: O
authors.lastname: Hermine
authors.forename: Eduardo
authors.initials: E
authors.lastname: Marinho
authors.forename: Béatrice
authors.initials: B
authors.lastname: Crickx
authors.forename: Vincent
authors.initials: V
authors.lastname: Descamps
mesh_terms: D000284:Administration, Oral; D000328:Adult; D001707:Biopsy, Needle; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007150:Immunohistochemistry; D000077269:Lenalidomide; D008297:Male; D053718:Scleromyxedema / Q000175:diagnosis* / Q000188:drug therapy*; D012720:Severity of Illness Index; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D016756:Immunoglobulins, Intravenous; D013792:Thalidomide; D000077269:Lenalidomide